The discoverer of the prostate-specific antigen (Richard Ablin) has a most interesting Op-Ed in the New York Times .

I keep hearing from several sources that Eli Lilly is announcing cuts today (well, filling in the details on previously announced cuts, anyway). True, or just rumor

Freeman Dyson has written about his belief that molecular biology is becoming a field where even basement tinkerers can accomplish things.

The Daily Telegraph in the UK has a story today claiming that a 1951 outbreak of hallucinations and dementia in the French village of Pont-Saint-Esprit was not (as everyone thought ) an example of ergot poisoning. No, according to some guy who’s writing a book, it was. . .a secret LSD experiment

If you want to know why people continue to speculate in biotech stocks, just take a look at the stairsteppy last few days of trading in Intermune (ITMN). Last Thursday it was at $15; now it’s at $38. And all you have to do to cash in on these moves is read the FDA’s mind! That’s not a money-making proposition, in case anyone thinks I’m advocating it.

The Supreme Court has agreed to hear a vaccine-liability case, in an attempt to untangle conflicting lower court rulings. This all turns on the 1986 act that shields manufacturers from liability suits and a followup law that establishes a separate compensation system for injuries.

We haven’t had a How Not to Do It around here in a while, so here’s a companion piece to the famous Sealed-Up Liquid Nitrogen Tank . This incident happened (as far as I can tell) about ten years ago

Nature Biotechnology weighs in on the GSK/Sirtris controversy. They have a lot of good information, and I’m not just saying that because someone there has clearly read over the comments that have showed up to my posts on the subject.

Well, it takes all kinds to make a market. And the collapse in Medivation’s shares after their disastrous Phase III results the other day seem to have brought out some hopeful buyers.

I’m hearing from more than one source that Exelixis has laid off about 40% of their work force, which is somewhere around 250 people (the numbers I get don’t all agree). This seems to be across the board, all departments, and most everyone is being asked to leave today